Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy
Martin F. M. de Rooij(Academic Medical Center), Annemieke Kuil(Academic Medical Center), Arnon P. Kater(University of Amsterdam), Marie José Kersten(Academic Medical Center), Steven T. Pals(University of Amsterdam), Marcel Spaargaren(University of Amsterdam)
Cited by 85Open Access
Abstract
To the editor: Most B-cell malignancies are dependent upon signaling by the B-cell receptor (BCR) and other growth and survival signals provided by the tumor microenvironment. Two recently US Food and Drug Administration–approved drugs that target the BCR signalosome, the Bruton tyrosine kinase (
Related Papers
No related papers found
Powered by citation graph analysis